← Back to all trials
Not Yet Recruiting
NCT07847476
Flubendazole Added to Standard Concurrent Chemoradiotherapy With Temozolomide in Patients With High-Grade Glioma
Conditions: Glioma Patients
Sex: All
Ages: 18 Years – 80 Years
Healthy volunteers: No
Phase: NA
Enrollment: 122
Sponsor: Assiut University
Summary
This study To evalute the efficacy and safety of adding flubendazole to standard concurrent chemoradiotherapy with temozolomide in patients with high grade glioma and also to evaluate DFS,OS for those patients in clinical oncology department , Assiut university Hospital .
Eligibility Criteria
Inclusion Criteria:
* \- Age ≥18 years.
* Male or female
* Histologically confirmed high grade glioma (WHO grade 3(III) and grade 4 IV) after surgery.
* ECOG PS 0-2
* Fit patient for concurrent chemoradiotherapy.
Exclusion Criteria:
* Age ≥80 years.
* presence of another active malignancy .
* known hypersensitivity to flubendazole.
* pregnant or breastfeeding women.
* inability to comply with study requirements.
Source: ClinicalTrials.gov (NCT07847476). StuddyBuddy aggregates publicly available trial information.
